GlassScriptPhysician profile
Hillary Nevins
NPI 1932934544
$2,385.49
in general payments reported to CMS, 2019-2025
20 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $446 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.54 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $392.80 | 2024-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $335.23 | 2024-2025 | |
| Csl Behring | $222.47 | 2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $203.96 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $169.96 | 2025 | |
| Glaxosmithkline, LLC. | $142.69 | 2025 | Trelegy Ellipta, Arexvy, Nucala |
| Optinose US, INC. | $141.05 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $123.35 | 2025 | Neffy |
| Octapharma USA, INC. | $116.09 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Astrazeneca Pharmaceuticals LP | $109.95 | 2025 | Airsupra, Fasenra, Tezspire |
| Amgen INC. | $90.89 | 2025 | Tezspire |
| Genentech USA, INC. | $77.89 | 2024-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $54.95 | 2025 | |
| Verona Pharma, INC. | $48.59 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $38.52 | 2025 | Dawnzera |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $37.52 | 2024-2025 | Sajazir |
| Grifols USA, LLC | $31.53 | 2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2025 | Ofev |
| Phathom Pharmaceuticals, INC. | $16.07 | 2024 | Voquezna |
| Viatris Specialty LLC | $13.97 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Nevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.